Clinical Trial Update: Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the efficacy and safety of NU100 in relapsing-remitting multiple sclerosis, with the current trial status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• NU100

Snippet

Sponsor: Nuron Biotech Inc. | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 3 | Status: UNKNOWN